A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 10 (Q73297940)
Jump to navigation
Jump to search
scientific article published on 01 March 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 10 |
scientific article published on 01 March 2003 |
Statements
A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells (English)
A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human Interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100–300 CD4+ t cells (English)
1 reference
1 reference
Norman Markowitz
Haig Donabedian
Carl Yoshizawa
Anne-Marie Duliege
Gwendolyn Fyfe
Alberdina W. de Boer
H. Clifford Lane
Louis D. Saravolatz
Ronald T. Mitsuyasu
1 reference